Skip to main content

Table 1 Key clinical data in the model

From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance

Parameters Cabazitaxel ASTI Reference
Weibull parameters
Scale (λ) for PFS 0.034827 0.069115 [19]
Shape (γ) for PFS 1.486146 1.468545 [19]
Scale (λ) for OS 0.007118 0.007698 [19]
Shape (γ) for OS 1.676228 1.867383 [19]
Survival
Median OS (range), month 13.6 (11.5–17.5) 11.0 (9.2–12.9) [19]
Median imaging PFS (range), month 8.0 (5.7–9.2) 3.7 (2.8–5.1) [19]
Median PFS (range), month 4.4 (3.6–5.4) 2.7 (2.4–2.8) [19]
Treatment
Median treatment duration (range), month 22 (3–88) 12.5 (2–141) [19]
Median treatment cycles 7 (1–29) 4 (1–45) [19]
Probability of AEs (grade 3/4)
Musculoskeletal pain or discomfort 0.016 (0.013–0.019) 0.056 (0.045–0.067) [19]
Renal disorder 0.032 (0.026–0.038) 0.081 (0.065–0.097) [19]
Anemia 0.080 (0.064–0.096) 0.048 (0.038–0.058) [19]
Leukopenia 0.320 (0.256–0.384) 0.016 (0.013–0.019) [19]
Neutropenia 0.447 (0.358–0.536) 0.032 (0.026–0.038) [19]
Utility
PFS 0.617 (0.494–0.740) 0.617 (0.494–0.740) [22]
PD 0.370 (0.296–0.444) 0.370 (0.296–0.444) [22]
  1. ASTI androgen-signaling-targeted inhibitor, PFS progression-free survival, OS overall survival, AEs adverse events